The new championship vaccine's innovation war is resurrected. Is the world's leading globe in the vaccine racing?

Since the emergence of the new crown epidemic, the epidemic has spread to all parts of the world. In order to defeat the virus, humans have developed a number of vaccines to become the main start of the virus from all walks of life. The vaccine has put forward higher requirements. The innovative war of the vaccine industry has risen again. Facing the competition in the development of vaccines, will the leaders this time be our company?

First, inhalation vaccine becomes a new direction of competition?

According to the Financial Press, with the large -scale spread of Omikon's new variant BA.5 in the United States, the United States has gradually turned their attention to the new coronal virus vaccine. The future of the new crown vaccine may no longer be an injection vaccine in the arm or leg, which may be the mucosa immunohistic technology route or a small patch sticking to the skin.

A few days ago, the United States held a meeting to discuss the vaccination of the next -generation new crown virus, and they generally believe that there is still room for improvement.

According to Dr. Anthony Fukic, "the new crown virus that is known and unknown obviously needs to develop a wider and lasting protection measures." Incori said that although the current vaccine available is beneficial, it avoids exceeding exceeding exceeding the exception and avoiding exceeding exceeding the exception. 2 million people died and nearly 20 million were hospitalized, but "the prevention work has not been completed."

Yale University vaccine expert Dr. Akiko iWasaki delivered a speech at the meeting to fully realize the only way to achieve the goal of Fickna is the mucosa immunohistic technology route vaccine. If the traditional injection vaccine is compared to the "guards on the lane", then the mucosal vaccine is the "guard outside the building". Compared with the former, the latter is easier to intercept "invaders".

The meeting said that development is a huge obstacle for new vaccines. If there is no large amount of funding assistance, it may take three to five years.

Seeing this, I believe that friends who are familiar with the Chinese vaccine industry will find that it really takes so long? According to the First Finance and Economics, on July 29, the vaccine manufacturer Kang Shino published the latest vaccine clinical trial data on the pre -printed website. Rong BA.1 mutant strains, and can cause higher antibody reactions than homologous immunity. Kangxino's inhalation vaccine was developed based on the company's muscle injection, and the adenovirus AD5 was used as a carrier, which was different from the active vaccine. Just two weeks ago, Kangsino announced that it had completed the phase II clinical trial of the inhalation vaccine.

As early as November last year, the world's first inhaled vaccine was developed in China by Chinese vaccine company Kangshino. Through several news comparison, it will be found that at least in the field of inhalation vaccine, China has led the United States for at least two years in the United States for at least two years. time.

2. Will the leader of the vaccine racing this time will be Kangshino?

At present, the entire market is a silent market differentiation about the vaccine industry. On the one hand, traditional vaccines have entered a stage of relatively excess capacity, but on the other hand, vaccines with innovative capabilities have entered a state of urgent need for the market. Especially for the development of forward -looking vaccines, it is more needed by the market.

The argument about the inhaled vaccine above is actually produced in this context. What should we think of this?

First of all, the war between humans and the new coronal virus will be a long -lasting war. Since the epidemic in 2020, in fact, with the global spread of the epidemic, a trend has gradually formed. This is the war between humans and viruses is not a war that can make a quick decision, but a real long -lasting war. Continuously changing, and human confrontation technology is constantly developing, and the two show an increasing state.

From now on, the normalization and long -term of the new crown epidemic have become the general trend. Under such circumstances, in order to achieve the sustainable leadership of humans on the virus, it truly controls the effects of the virus on production and life in a controllable range of controllable range. In addition, in addition to our conventional prevention and control measures, only innovative technology may be possible to obtain the opportunity of this war. In particular, active prevention measures represented by vaccines are undoubtedly very effective after practice.

However, as the so -called magic height is one foot tall, when the virus is rapidly mutated, the continuous innovation and even forward -looking innovation of vaccine production are actually more important than anything. The advantages are constantly obtaining during the race.

Secondly, innovation of inhalation vaccine (mucosal immunization) innovation is very important. When we carefully study the principle of inhaling vaccines, we will find that similar to American experts say that the logic of inhaling vaccines is "defending the enemy outside the country."

Under normal circumstances, the injection vaccine we use is to produce antibodies in the human body. After the virus enters the human body, the virus invasion will be recognized, which will cause the corresponding antibody to confront. The respiratory tract has actually been broken by the virus. Now the role of the immune system is to protect the human body to avoid critical illness.

However, the logic of inhalation vaccine is based on the original vaccine, and through the mucosal immune response of the respiratory tract, the virus is directly resisted on the "first line of defense" that the virus enters the human body, which causes more in the mucosal tissue to cause more more than more. Immune protection to protect the human body. This is equivalent to training the most outer guard of the human body. As soon as the virus enters the door of the human castle, it is found at the door, so that the invaders are not only more difficult to enter, but also more difficult to spread.

This is why the United States attaches great importance to inhaling vaccines. Third, in the preface of the preface and a variety of new technologies, we finally walked at the forefront of the world. During the epidemic, countries around the world are promoting the development of vaccines on a large scale. Although Chinese companies are constantly innovating and developing, after all, the speed is slightly slower than international competitors. In the field of vaccine technology innovation, we have a certain technical disadvantage. The vaccine industry has been in a state of low -quality competition for a while, which has gradually lost its market advantage.

However, this time China's domestic vaccine has successfully achieved a leading leader in the world. When American vaccine experts are still discussing the development direction of mucosal immunity as the development of its own vaccine, on July 14, Conchino said on the interactive platform that inhaling inhalation was inhaled that inhaling inhalation The II clinical site work with reorganized new coronary virus vaccines (5 gonad virus vectors) has been completed. As the world's first vaccine to push the mucosa immunochromic vaccine to the clinical trial stage, China's domestic vaccine has obtained the market first first According to the prediction of the United States, the time difference of this technology has reached more than two years. This is undoubtedly an unprecedented advantage of the Kangxino vaccine, and it is also a rare leader in China's domestic vaccine in technology competition.

In addition, according to the First Financial report, compared with the continuous decline in immunomoscopic antibodies in the injection of traditional vaccines for 3 months, the effect of the protection of Omikon 3 months after the vaccine was enhanced! Even after 6 months of inhalation and strengthening, the protection effect of primitive strains is still much higher than the level of WHO standard products. Among the two groups of low -doses and high doses of Kangshino inhaled vaccine inhaled vaccine, the positive detection rate of antibodies still reached 73.7%and 72.2%, which also proved that the advantages of vaccine inhaled mucosal immunity are quite significant. Resistance.

Fourth, Cumano's lead will be of more important significance for the development of the Chinese vaccine industry. When obtaining the current market advantage, once Kangsino's inhaled mucosal immunization vaccine is used as a enhanced needle to conduct sequential immune promotion, it is likely to bring a new change to the Chinese vaccine industry.

On the one hand, the Chinese can get better vaccine immunity protection in the case of leading the West, thereby further optimizing and improving our epidemic prevention barrier, truly helping us better restore production and living order, and the impact of virus mutations brought about Further reduces our advantages to better play.

On the other hand, for the Chinese biological vaccine industry, some Chinese vaccine companies can take the lead in achieving a forward -looking layout, which not only means that we have one step ahead of the world vaccine competition, but also represent the innovative research and development capabilities of our vaccine and The forward -looking layout capabilities have further developed, which has more important positive significance for the current innovation and development of China's vaccine industry, and will have a greater impact on the entire industrial chain.

More importantly, Kangshino's inhalation technology can not only be used on the new crown vaccine, but also can play an advantage on more vaccine preparation of respiratory infectious diseases such as tuberculosis, which can truly become a technical platform and carrier. The continuous cumulative technical experience and industrial scale will continue to consolidate their own market protection.

At present, the competition of vaccines has changed from a simple production competition with the virus -racing to a more combatable quality competition. Under such circumstances, low -quality duplication is no longer valuable. Prospective layout, continuously improve our vaccine research and development capabilities, truly promote the technological progress of vaccine production, and thus enhance our competitiveness in the fierce market competition. Among them Positive meaning.

It is hoped that China's vaccine companies will go further and continue to strengthen R & D and innovation, and truly improve our core competitiveness of our industry.

- END -